Zobrazeno 1 - 10
of 31
pro vyhledávání: '"OFF Regimen"'
Autor:
Nour Kibbi, Nelson Ugwu
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 5:46-50
Keratoacanthomas (KAs) are fast-growing tumors and can be difficult to distinguish from squamous cell carcinomas (SCCs). Most KAs are sporadic, but KAs may also arise following traumatic procedures. We report the case of a 94-year-old male who develo
Autor:
Chang Diao, Min Zhang, Yanjun Su, Ruo-Chuan Cheng, Jun Qian, Tuanli Li, Ling Zhang, Shaohao Cheng, Ying Zhang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
We describe a case of recurrent and metastatic radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) treated with anlotinib in this report. The patient was randomized to placebo initially, after disease progressed at C8 (C is the tre
Autor:
Depei Wu, Kai-Lin Xu, Hong-Hu Zhu, Xiao-Yan Yan, Juan Li, Yongping Song, Hanyun Ren, Lin Liu, Jianda Hu, Xi Zhang, Zong-Hong Shao, Jing-Wen Wang, Xin Du, Xiao-Jun Huang, Jun Ma, Mei-Yun Fang
Publikováno v:
The Lancet Oncology. 19:871-879
Summary Background Intravenous arsenic trioxide plus all-trans retinoic acid (ATRA) without chemotherapy is the standard of care for non-high-risk acute promyelocytic leukaemia (white blood cell count ≤10 × 10 9 per L), resulting in cure in more t
Publikováno v:
Neurourology and Urodynamics. 36:486-489
Aims In this two-part study, we sought to define how long sacral neuromodulation users with overactive bladder should trial a new setting before attributing symptoms to that setting. Subsequently, we evaluated patient preferences of variable stimulat
Publikováno v:
American Journal of Ophthalmology Case Reports
American Journal of Ophthalmology Case Reports, Vol 8, Iss C, Pp 1-3 (2017)
American Journal of Ophthalmology Case Reports, Vol 8, Iss C, Pp 1-3 (2017)
Purpose To report the first sequential cross-over treatment with the longest ophthalmic follow-up in a case of X-linked juvenile retinoschisis (XLRS) successfully treated with topical dorzolamide. Observations A healthy 34 year-old man presented with
Autor:
J. Álvarez-Sala, F. Sanchez-Refoyo, D. Paz Corral, J. Vicarregui, R. Hernanz Chaves, L. Ugarte, O. Echevarria, J. A. Lopez-Lopez, A. Lopez-Picado, O. Lapuente-Ocamica, I. Bilbao, A. Fariñas, Iñaki Lete Lasa, L. Barbero
Publikováno v:
BMC Pregnancy and Childbirth
BMC Pregnancy and Childbirth, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Pregnancy and Childbirth, Vol 19, Iss 1, Pp 1-9 (2019)
Background Among the various methods available, the administration of prostaglandins is the most effective for inducing labour in women with an unfavourable cervix. Recent studies have compared treatment with various titrated doses of oral misoprosto
Autor:
Kazunari Tanabe, Toshio Takagi, Kazuhiko Yoshida, Hiroki Ishihara, Junpei Iizuka, Kana Iwamoto, Tsunenori Kondo
Publikováno v:
Medical Oncology. 35
Sunitinib treatment with a 2-week-on/1-week-off schedule (Schedule 2/1) is a common alternative regimen with high relative dose intensity (RDI) and superior tolerability for patients with metastatic renal cell carcinoma (mRCC). The prognostic impact
Autor:
Kana Iwamoto, Kenji Omae, Toshio Takagi, Hidekazu Tachibana, Junpei Iizuka, Kazunari Tanabe, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Hiroki Ishihara, Tsunenori Kondo
Publikováno v:
Journal of Urology. 199
Autor:
Yohei Yamanaka, Ryoichi Imamura, Atsunari Kawashima, Eisuke Tomiyama, Kazutoshi Fujita, Osamu Miyake, Motohide Uemura, Akira Nagahara, Norio Nonomura, Toshiaki Yoshioka, Yasushi Miyagawa, Go Tanigawa, Taigo Kato, Takeshi Ujike
Publikováno v:
International Journal of Clinical Oncology
Background Sunitinib is widely prescribed as first-line therapy for metastatic renal cell carcinoma. To reduce the ratio of severe adverse events and improve the relative dose intensity, we prospectively tried our own alternative medication schedule,
Publikováno v:
Journal of Neuro-Oncology. 125:339-349
The goal of this meta-analysis was to identify the temozolomide (TMZ) regimen with optimal efficacy and tolerance for treatment of recurrent high-grade glioma (HGG). The PubMed and EMBASE databases were searched from the earliest records to February